Scientists test new Triple-Threat drug combo against tough cancers
NCT ID NCT04850755
Summary
This early-stage study tested the safety and best dose of a three-drug combination (selinexor, nivolumab, and ipilimumab) in 11 patients with advanced solid cancers that had stopped responding to standard treatments. The main goal was to see how well patients tolerated the drugs together and to find the safest dose for future testing. Researchers also looked for early signs that the combination might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCE SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital, Singapore
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.